Gut hormones in the treatment of short-bowel syndrome and intestinal failure

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 22, Issue 1, 2015, Pages 14-20

  Jeppesen, Palle B ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Gattex; glucagon like peptide 1; glucagon like peptide 2; intestinal failure; Revestive; short bowel syndrome; teduglutide

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; TEDUGLUTIDE; GASTROINTESTINAL AGENT; PEPTIDE;

DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; INTESTINAL FAILURE; INTESTINE ABSORPTION; METABOLIC BALANCE; PILOT STUDY; REVIEW; SHORT BOWEL SYNDROME; TREATMENT DURATION; TREATMENT INDICATION; AGONISTS; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; SMALL INTESTINE; UNITED STATES; VASCULARIZATION;

CLINICAL TRIALS, PHASE II AS TOPIC; GASTROINTESTINAL AGENTS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; PARENTERAL NUTRITION; PEPTIDES; PILOT PROJECTS; QUALITY OF LIFE; SHORT BOWEL SYNDROME; UNITED STATES;

EID: 84920924248     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000120     Document Type: Review

References (47)

1. Jeppesen PB. Short bowel syndrome-characterisation of an orphan condition with many phenotypes. Expert Opin Orphan Drugs 2013; 1:515-525.
2. Lal S, Teubner A, Shaffer JL. Review article: intestinal failure. Aliment Pharmacol Ther 2006; 24:19-31.
3. Van Citters GW, Lin HC. The ileal brake: a fifteen-year progress report. Curr Gastroenterol Rep 1999; 1:404-409.
4. Spiller RC. Feedforward and feedback control mechanisms in the gut. With special emphasis on inhibitory feedback by nutrients in the distal small bowel and colon. Dig Dis 1990; 8:189-205.
5. Spiller RC, Trotman IF, Higgins BE, et al. The ileal brake-inhibition of jejunal motility after ileal fat perfusion in man. Gut 1984; 25:365-374.
6. Shahidullah M, Kennedy TL, Parks TG. The vagus, the duodenal brake, and gastric emptying. Gut 1975; 16:331-336.
7. Jeppesen PB, Hartmann B, Hansen BS, et al. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999; 45:559-563.
8. Jeppesen PB, Mortensen PB. Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut 2000; 46:701-706.
9. Carbonnel F, Cosnes J, Chevret S, et al. The role of anatomic factors in nutritional autonomy after extensive small bowel resection. JPEN J Parenter Enteral Nutr 1996; 20:275-280.
10. Messing B, Crenn P, Beau P, et al. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenter-ology 1999; 117:1043-1050.
11. Jeppesen PB, Langholz E, Mortensen PB. Quality of life in patients receiving home parenteral nutrition. Gut 1999; 44:844-852.
12. Berghofer P, Fragkos KC, Baxter JP, et al. Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL) scale. Clin Nutr 2013; 32:789-796.
13. Carlsson E, Berglund B, Nordgren S. Living with an ostomy and short bowel syndrome: practical aspects and impact on daily life. J Wound Ostomy Continence Nurs 2001; 28:96-105.
14. Baxter JP, Fayers PM, McKinlay AW. A review of the quality of life of adult patients treated with long-term parenteral nutrition. Clin Nutr 2006; 25:543-553.
15. Jeppesen PB, Pertkiewicz M, Forbes A, et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide-analyses from a randomised, placebo-controlled study. Clin Nutr 2013; 32:713-721.
16. Carlsson E, Bosaeus I, Nordgren S. Quality of life and concerns in patients with short bowel syndrome. Clin Nutr 2003; 22:445-452.
17. Kalaitzakis E, Carlsson E, Josefsson A, Bosaeus I. Quality of life in short-bowel syndrome: impact of fatigue and gastrointestinal symptoms. Scand J Gastro-enterol 2008; 43:1057-1065.
18. Elphick DA, Baker M, Baxter JP, et al. Muscle cramps are the commonest side effect of home parenteral nutrition. Clin Nutr 2009; 28:351-354.
19. Forbes A. Parenteral nutrition. Curr Opin Gastroenterol 2005; 21:192-196.
20. Goulet O, Joly F, Corriol O, Colomb-Jung V. Some new insights in intestinal failure-associated liver disease. Curr Opin Organ Transplant 2009; 14:256-261.
21. Lauverjat M, Hadj AA, Vanhems P, et al. Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clin Nutr 2006; 25:75-81.
22. Jeppesen PB. The nonsurgical treatment of adult patients with short bowel syndrome. Expert Opin Orphan Drugs 2013; 1:515-525.
23. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93:7911-7916.
24. Bremholm L, Hornum M, Henriksen BM, et al. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 2009; 44:314-319.
25. Bremholm L, Hornum M, Andersen UB, et al. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunost-omy short bowel patients. Regul Pept 2011; 168:32-38.
26. Hoyerup P, Hellstrom PM, Schmidt PT, et al. Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patients. Regul Pept 2013; 180:12-16.
27. Cani PD, Possemiers S, Van de WT, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58:1091-1103.
28. Ivory CP, Wallace LE, McCafferty DM, Sigalet DL. Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastro-intest Liver Physiol 2008; 295:G1202-G1210.
29. Sigalet DL, Wallace LE, Holst JJ, et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastro-intest Liver Physiol 2007; 293:G211-G221.
30. Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009; 2009:616054.
31. Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009; 45:833-842.
32. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001; 120:806-815.
33. Marier JF, Beliveau M, Mouksassi MS, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 2008; 48:1289-1299.
34. Marier JF, Mouksassi MS, Gosselin NH, et al. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. J Clin Pharmacol 2010; 50:36-49.
35. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005; 54:1224-1231.
36. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011; 60:902-914.
37. Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012; 143:1473-1481.
38. O'Keefe SJ, Jeppesen PB, Gilroy R, et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel syndrome intestinal failure. Clin Gastroenterol Hepatol 2013; 11:815-823.
39. Jeppesen PB. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therap Adv Gastroenterol 2012; 5:159-171.
40. NPS Pharmaceuticals. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommit tee/UCM323506.pdf. [Accessed 15 November 2014]
41. NPS Pharmaceuticals. GATTEX (teduglutide [rDNA origin]) for injection. Prescribing Information. 2012.
42. Sueyoshi R, Woods Ignatoski KM, Okawada M, et al. Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model. Am J Physiol Gastrointest Liver Physiol 2014; 307:G410-G419.
43. Okawada M, Holst JJ, Teitelbaum DH. Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome. Surgery 2011; 150:217-223.
44. Kunkel D, Basseri B, Low K, et al. Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome. Neurogastroen-terol Motil 2011; 23:739-e328.
45. Madsen KB, Askov-Hansen C, Naimi RM, et al. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regul Pept 2013; 184:30-39.
46. Grikscheit TC, Siddique A, Ochoa ER, et al. Tissue-engineered small intestine improves recovery after massive small bowel resection. Ann Surg 2004; 240:748-754.
47. Sudan D. The current state of intestine transplantation: indications, techniques, outcomes and challenges. Am J Transplant 2014; 14:1976-1984.